These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 309844)
1. Influence of coformycin on the cytostatic activity of 9-beta-D-arabinofuranosyladenine and adenosine in mouse L5178y cells. Müller WE; Zahn RK; Arendes J; Maidhof A; Umezawa H Hoppe Seylers Z Physiol Chem; 1978 Oct; 359(10):1287-95. PubMed ID: 309844 [No Abstract] [Full Text] [Related]
2. Clinical pharmacology of arabinofuranosyladenine in combination with deoxycoformycin. Major PP; Agarwal RP; Kufe DW Cancer Chemother Pharmacol; 1983; 10(2):125-8. PubMed ID: 6600984 [No Abstract] [Full Text] [Related]
3. Inhibitor of 2', 5'-oligoadenylate synthetase induced in human T lymphoblastoid cell line treated with deoxyadenosine, deoxycoformycin and interferon. Heike T; Katamura K; Kubota M; Shinomiya K; Mikawa H Adv Exp Med Biol; 1986; 195 Pt B():683-7. PubMed ID: 3490130 [No Abstract] [Full Text] [Related]
4. Effects of a new adenosine deaminase inhibitor, isocoformycin, on toxicity, antitumor activity and tissue distribution of formycin A and 9-beta-D-arabinofuranosyladenine. Hidaka T; Katayama K; Yamashita K; Yamashita T; Watanabe K; Shimazaki M; Ohno M; Takeuchi T; Umezawa H J Antibiot (Tokyo); 1980 Mar; 33(3):303-9. PubMed ID: 7380742 [TBL] [Abstract][Full Text] [Related]
5. Effect of 2'-deoxycoformycin on the inhibition of deoxyribonucleic acid synthesis by 9-beta-D-arabinofuranosyladenine 5'-triphosphate. Shewach DS; Plunkett W Biochem Pharmacol; 1982 Jun; 31(11):2103-9. PubMed ID: 6180754 [No Abstract] [Full Text] [Related]
6. Biochemical basis of the increased activity of 9-beta-D-arabinofuranosyladenine in the presence of inhibitors of adenosine deaminase. Plunkett W; Alexander L; Chubb S; Loo TL Cancer Res; 1979 Sep; 39(9):3655-60. PubMed ID: 476690 [No Abstract] [Full Text] [Related]
7. Potentiation of growth-inhibitory activity of 9-beta-D-arabinofuranosyladenine by 2'-deoxycoformycin in human cultured cell lines derived from leukemias and lymphomas. Kuroki Y; Shimoyama M; Inaba S; Hirose M Jpn J Cancer Res; 1989 May; 80(5):482-9. PubMed ID: 2502523 [TBL] [Abstract][Full Text] [Related]
8. Mechanism of adenosine triphosphate catabolism induced by deoxyadenosine and by nucleoside analogues in adenosine deaminase-inhibited human erythrocytes. Bontemps F; Van den Berghe G Cancer Res; 1989 Sep; 49(18):4983-9. PubMed ID: 2788493 [TBL] [Abstract][Full Text] [Related]
9. The effect of the cytostatic agent 9-alpha-D-arabinofuranosyladenine on the nucleic acid metabolism in L5178y cells. Müller WE; Zahn RK; Maidhof A; Beyer R; Arendes J Biochem Pharmacol; 1978; 27(12):1659-63. PubMed ID: 697906 [No Abstract] [Full Text] [Related]
10. Comparison of the toxicity and metabolism of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 9-beta-D-arabinofuranosyladenine in human lymphoblastoid cells. Plunkett W; Chubb S; Alexander L; Montgomery JA Cancer Res; 1980 Jul; 40(7):2349-55. PubMed ID: 6966966 [No Abstract] [Full Text] [Related]
11. Prolongation of mouse and rat pancreatic islet cell allografts by adenosine deaminase inhibitors and adenine arabinoside. Lum CT; Sutherland DE; Payne WD; Gorecki P; Matas AJ; Najarian JS J Surg Res; 1980 Jan; 28(1):44-8. PubMed ID: 6767140 [No Abstract] [Full Text] [Related]
12. Modulation of 9-beta-D-arabinofuranosyladenine 5'-triphosphate and deoxyadenosine triphosphate in leukemic cells by 2'-deoxycoformycin during therapy with 9-beta-D-arabinofuranosyladenine. Plunkett W; Benjamin RS; Keating MJ; Freireich EJ Cancer Res; 1982 May; 42(5):2092-6. PubMed ID: 6175407 [TBL] [Abstract][Full Text] [Related]
13. Correlation of cytotoxicity with total intracellular exposure to 9-beta-D-arabinofuranosyladenine 5'-triphosphate. Shewach DS; Plunkett W Cancer Res; 1982 Sep; 42(9):3637-41. PubMed ID: 6179604 [TBL] [Abstract][Full Text] [Related]
14. The effect of nucleosides and deoxycoformycin on adenosine and deoxyadenosine inhibition of human lymphocyte activation. Uberti J; Lightbody JJ; Johnson RM J Immunol; 1979 Jul; 123(1):189-93. PubMed ID: 312874 [TBL] [Abstract][Full Text] [Related]
15. Deoxyadenosine antagonism of the antiviral activity of 9-beta-D-arabinofuranosyladenine and 9-beta-D-arabinofuranosylhypoxanthine. Smith SH; Shipman C; Drach JC Cancer Res; 1978 Jul; 38(7):1916-21. PubMed ID: 207416 [TBL] [Abstract][Full Text] [Related]
16. Effect of 9-beta-D-arabinofuranosyladenine on DNA synthesis in vivo. Müller WE; Maidhof A; Zahn RK; Shannon WM Cancer Res; 1977 Jul; 37(7 Pt 1):2282-90. PubMed ID: 301056 [No Abstract] [Full Text] [Related]
17. Decreased NAD+ content in human T lymphoblastoid cells treated simultaneously with 2'-deoxycoformycin and 2'-deoxyadenosine. Koya M; Kanoh T; Uchino H; Ueda K Nihon Ketsueki Gakkai Zasshi; 1985 Jul; 48(4):1003-11. PubMed ID: 3877388 [No Abstract] [Full Text] [Related]
18. Clinical pharmacology of 9-beta-D-arabinofuranosyladenine in combination with 2'-deoxycoformycin. Agarwal RP; Blatt J; Miser J; Sallan S; Lipton JM; Reaman GH; Holcenberg J; Poplack DG Cancer Res; 1982 Sep; 42(9):3884-6. PubMed ID: 6980706 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of K and NK lymphocyte cytotoxicity by an inhibitor of adenosine deaminase and deoxyadenosine. Grever MR; Siaw MF; Coleman MS; Whisler RL; Balcerzak SP J Immunol; 1983 Jan; 130(1):365-9. PubMed ID: 6600187 [No Abstract] [Full Text] [Related]
20. Comparison of the activity of 2'-deoxycoformycin and erythro-9-(2-hydroxy-3-nonyl)adenine in vivo. Plunkett W; Alexander L; Chubb S; Loo TL Biochem Pharmacol; 1979; 28(2):201-6. PubMed ID: 426835 [No Abstract] [Full Text] [Related] [Next] [New Search]